C
urrently, in many parts of the globe, the emergence and spread of malaria parasites resistant to various antimalarial drugs recommended by the international organizations remain major factors threatening control efforts (41) . Among the five Plasmodium species that affect humans (40) , resistant Plasmodium falciparum parasites were first selected by chloroquine (CQ), a highly effective, fast-acting, and inexpensive 4-aminoquinoline widely used for several decades, in Southeast Asia or South America (29, 44) in the 1960s. CQ-resistant parasites of the other Plasmodium species emerged much later: in 1989 for Plasmodium vivax (Papua New Guinea) (32) and in 2002 for Plasmodium malariae (Indonesia) (26) . Following the introduction of the sulfadoxinepyrimethamine combination (SP) to replace CQ as the first-line treatment for uncomplicated P. falciparum malaria, the same scenario was observed. SP-resistant P. falciparum parasites were first detected in the 1980s (9, 19) . Molecular investigations, based on laboratory and field isolates, demonstrated later that the resistance of P. falciparum to pyrimethamine was mediated by specific point mutations in the dihydrofolate reductase gene (dhfr) (30, 31) . Currently, it is assumed that pyrimethamine resistance is conferred by the stepwise selection of a series of nonsynonymous point mutations (codons 50, 51, 59, and 164) from the S108N single mutant allele (24) . Parasites with the triple mutant allele (N51I C59R S108N) have markedly reduced in vitro susceptibility to pyrimethamine, and the presence of this allele in a P. falciparum-infected patient increases the risk of SP therapeutic failure (15) . The additional mutation I164L confers on the quadruple mutant a high level of resistance to pyrimethamine (22) and abrogates the clinical efficacy of SP, as observed in Southeast Asia, South America (31) , and Africa (25) . Although P. vivax and P. malariae infections are not usually treated directly with SP, the high frequency of mixed infections, such as P. falciparum-P. vivax or P. falciparum-P. malariae infections, that are not detected by microscopy examination (27) has inevitably exposed a large number of non-P. falciparum parasites to antifolate therapy in many areas.
Comparison of the dihydrofolate reductase (DHFR) enzymes in P. falciparum and P. vivax showed that the DHFR domains were 77.3% identical and the active-site regions were strongly conserved (23) . Moreover, sequencing of the dhfr gene in numerous P. vivax isolates collected in areas where SP was used to treat P. falciparum and alignment of these alleles with P. falciparum dhfr alleles have demonstrated that mutations in codons 57, 58, 61, 117, and 173 were involved in resistance to pyrimethamine and corresponded to codons 51, 59, 108, and 164 in P. falciparum (for a review, see reference 17). Heterologous expression studies later confirmed the role of these mutations in the resistance of P. vivax to pyrimethamine (17) .
More recently, Tanomsing et al. conducted a study that aimed to determine whether SP pressure had selected pyrimethamineresistant P. malariae parasites (37) . By cloning, sequencing, and alignment of 35 Plasmodium malariae dihydrofolate reductase (Pmdhfr) sequences with the Plasmodium brasilianum dihydrofolate reductase (Pbdhfr) sequence, they observed several nonsynonymous mutations in five different codons (H22Q, K48E, N50K, S114N/G, and I170M). Three of these (codons 50, 114, and 170) corresponded to analogous positions known to be associated with pyrimethamine resistance in P. falciparum (residues 51, 108, and 164) and P. vivax (residues 117 and 173) (37) . After this finding, Choowongkomon et al. demonstrated by computational analysis of interactions between DHFR inhibitors and the modeled structure of malaria parasite DHFR enzymes that certain residues in P. malariae DHFR (PmDHFR) were associated with significant reductions in binding energy for pyrimethamine (I13, L45, N53, S117, and I170) (8) . However, the data acquired on PmDHFR polymorphism remain patchy; they are based on a few isolates, collected essentially in Southeast Asian countries (30/35 isolates), where SP has not been used for several decades. In this context, this study presents additional comprehensive data on the genetic diversity of PmDHFR by sequencing a large set of isolates (n ϭ 123) collected in areas with different histories of SP use (mainland Africa, Madagascar, and Cambodia). PCR products were purified, using a polyacrylamide gel (Bio-Gel P-100; Bio-Rad, Marnes-la-Coquette, France), by 96-well plate filtration (Millipore, St. Quentin en Yvelines, France). Sequencing reactions were performed using the ABI Prism BigDye Terminator cycle sequencing ready reaction kit and were run on a 3730xl genetic analyzer (Applied Biosystems, Courtaboeuf, France). Electrophoregrams were visualized and analyzed with CEQ 2000 Genetic Analysis System software (Beckman Coulter). Amino acid sequences were compared with the wild-type sequence (GenBank accession no. AY846633 for Pmdhfr) using the BioEdit Sequence Alignment Editor (16) . The presence of single nucleotide polymorphisms (SNP) was confirmed by reads through both forward and reverse strands. The Pmdhfr gene polymorphisms identified among our isolates were compared to dhfr gene sequences of P. malariae available in GenBank.
MATERIALS AND METHODS
Statistical analysis. Raw data were input into Microsoft Excel 2007 software and were checked and analyzed using MedCalc software, version 9.1.0.1 (MedCalc Software, Mariakerke, Belgium). Continuous variables were compared by using the independent-sample t test. Sequence polymorphism analysis, including the calculation of haplotype diversity (h) and nucleotide diversity (), was performed using DnaSP software, version 5.10.01 (33) . Departures from selective neutrality were assessed by the ratio of nonsynonymous to synonymous substitutions (dN/dS ratio) in the P. malariae dhfr gene. Significance (probability of rejecting the null hypothesis of strict neutrality [dN ϭ dS]) was determined by using the two-tailed Z-test (bootstrap method with 10,000 replicates using the NeiGojobori method) as implemented in MEGA, version 5.0.5 (36) . In all tests performed, P values of Ͻ0.05 were considered statistically significant at the 5% level.
Ethical approval. Ethical clearance for the samples used in this study was obtained from the Ethics Committee of the Cambodian Ministry of Health and the Ethics Committee of the Ministry of Health of Madagascar (007/SANPF/2007; registration number ISRCTN36517335). Informed written consent was provided by all patients or their parents/guardians before inclusion in the study.
Nucleotide sequence accession numbers. The sequences for the new haplotypes of the Pmdhfr gene identified here have been deposited in GenBank under accession numbers JN038065 to JN038071.
RESULTS

P. malariae dihydrofolate reductase polymorphisms.
A 633-bp fragment (spanning the region from codon 15 to codon 225 in the Pmdhfr gene) was sequenced from 123 clinical P. malariae isolates: 26 from Cambodia (including 5 P. falciparum-P. malariae and 3 P. vivax-P. malariae mixed infections), 53 from Madagascar (including 13 mixed infections with P. falciparum and P. malariae and 1 with P. vivax and P. malariae), and 44 from various African countries (19 from Côte d'Ivoire, 17 from Cameroon, 4 from Comoros, 2 from Mali, 1 from Gabon, and 1 from Togo) (including 9 P. falciparum-P. malariae mixed infections).
A total of 623 monomorphic and 10 polymorphic sites were found. Polymorphic sites included those with 2 synonymous substitutions (V60V [GTA to GTG]; S114N [AGC to AAT] [a nonsynonymous substitution was also found at this site]) and 8 nonsynonymous substitutions. The 2 silent mutations were observed only once (in one Cambodian isolate and one Malagasy sample). Of the 8 sites with nonsynonymous substitutions, all were dimorphic: K55E, S58R, S59A, S114N, F168S, N194S, D207G, and T221A. Most of the nonsynonymous substitutions (6/8 [75%]) were nonconservative, with changes of the physicochemical family of the amino acid. The substitutions observed at codons 55, 58, 168, 194, 207, and 221 were found once (0.81%), while those affecting codon 114 were observed in three Cambodian isolates (2.4%) and those affecting codon 59 in four Malagasy samples (3.2%). The polymorphisms in the Plasmodium malariae dhfr gene (including those previously described by Tanomsing et al. [37] ) are detailed in Fig. 1 .
By following the numbering of haplotypes used by Tanomsing et al. (37) , the polymorphisms observed in our samples were arranged into nine different haplotypes (H4, H5, and H8 to H14) and eight Plasmodium malariae DHFR proteins (H4, H5/H12, H8 to H11, H13, and H14) (Fig. 1) polymorphisms identified in our sample population (n ϭ 123) to sequences available in GenBank (n ϭ 35), seven new mutations (K55E, S58R, S59A, F168S, N194S, D207G, and T221A) and seven new haplotypes (H8 to H13), leading to six new DHFR proteins, were observed (Fig. 1) .
All new mutations and haplotypes observed in our sample set were recognized as exclusive to Madagascar (Fig. 1) , except for the double mutations at nucleotides 341 and 342 (S114N) found in one Cambodian isolate. This isolate, classified as a new haplotype (H12), leads to a DHFR protein described previously in Thailand (H5). Only three isolates from Cambodia were classified as mutant type (S114N), while all isolates from African countries were classified as wild type.
The molecular diversity indices and neutrality tests for each P. malariae population are given in Table 1 . The overall nucleotide diversity and the mean haplotype diversity in our sample population were 0.0004 and 0.171, respectively. Haplotype and nucleotide diversities were significantly higher in the Malagasy than in the Cambodian P. malariae population (P, 0.005 and 0.001, respectively) and significantly higher among Cambodian P. malariae sequences than among African P. malariae sequences (P, Ͻ0.0001). Analyses of the dN/dS ratio showed a negative ratio for Cambodian samples (Ϫ0.94), indicative of purifying selection, while Malagasy samples had a ratio greater than 1 (1.02), suggesting positive selection. For African samples, in which no synonymous mutations were detected, the dN/dS ratio was zero. However, in all three populations, the probability of rejecting the null hypothesis of strict neutrality (dN ϭ dS) was nonsignificant.
FIG 1 dhfr polymorphisms identified in 123 Plasmodium malariae isolates from Cambodia (CAM), Madagascar (MAD), and various African countries (AFR)
(including Comoros, Côte d'Ivoire, Guinea, Cameroon, Mali, Gabon, and Togo) or described previously by Tanomsing et al. (37) and available in GenBank. ‫,ء‬ nucleotide and amino acid numbers are given according to the wild-type sequence for Pmdhfr (GenBank accession no. AY846633); ‫,ءء‬ sample locations (with the numbers of isolates given in parentheses) are abbreviated as follows: VN, Vietnam; GB, Guinea-Bissau; TH, Thailand; LAO, Lao People's Democratic Republic; PNG, Papua New Guinea. The correspondences between polymorphisms in the P. malariae dhfr gene and equivalent residues already known to be related to pyrimethamine resistance in the P. falciparum and P. vivax dhfr genes are presented in Fig. 2 . Among the eight mutations described in the P. malariae dhfr gene, two were likely related to pyrimethamine resistance: S58R (H9; corresponding to C59R in P. falciparum and S58R in P. vivax; observed in one Malagasy sample) and S114N (H5 and H12; corresponding to S108N in P. falciparum and S117N in P. vivax; observed in three Cambodian samples). Three other mutations close to SNP involved in pyrimethamine resistance were also found: K55E (H8; observed in one Malagasy sample), S59A (H10 and H11; observed in four Malagasy samples), and F168S (H9; in association with S58R, observed in one Malagasy sample).
DISCUSSION
Although the distribution of P. malariae infection is reported as patchy, it has been observed in all major regions of the world where malaria is endemic (18) . More common in sub-Saharan Africa and the southwest Pacific (3, 5, 6, 12, 38) , P. malariae is also detected in Asia (7, 11, 13, 14, 21) , the Middle East (1), and South and Central America (34, 39) . Responsible for quartan malaria, P. malariae is usually considered a benign pathogen compared to human sympatric P. falciparum and P. vivax. Severe clinical symptoms are rarely associated with the acute infection, except in cases of chronic nephropathy. To date, data from drug susceptibility studies on this species are scare, while treatments for P. falciparum and P. vivax malaria are often used in a context of mixed infections with P. malariae. In vitro assays of P. malariae are not currently available, and therapeutic efficacy studies are very difficult to conduct. Molecular investigations focused on putative molecular markers remain the only means of assessing the impact of antimalarial drugs on this species, especially by extrapolating to what we have already observed for P. falciparum or P. vivax parasites.
In this study, we have analyzed a total of 123 sequences from clinical P. malariae isolates from Cambodia, Madagascar, and various African countries. Among these, 10 polymorphic sites, including 2 sites with synonymous substitutions and 8 with nonsynonymous substitutions (codons 55, 58, 59, 114, 168, 194, 207, and 221), were found. One of the most interesting results was that glutamine (Q) was the most prevalent amino acid at position 22. This amino acid was previously considered mutant type (H22Q) by Tanomsing et al., who had used the P. brasilianum dhfr sequence as the wild-type reference sequence, despite the fact that more than 85% (30/35) of their sequences had a glutamine at this position (37) . Their main rationale for using P. brasilianum as the wild-type sequence was that given the widespread use of SP and the apparent ease in which P. malariae acquires resistance to pyrimethamine (42, 43) , they suspected that all the sequences obtained from P. malariae isolates could already carry mutations, unlike the laboratory-maintained P. brasilianum strain. However, several indications seem to show otherwise: (i) the high prevalence of the haplotype carrying a glutamine at position 22, (ii) the very high susceptibility of this haplotype to pyrimethamine by use of the classical in vitro assay (50% inhibitory concentration [IC 50 ], Ͻ7 ng/ml) (37), (iii) the lack of equivalent residues in Pfdhfr and Pvdhfr previously associated with pyrimethamine resistance, (iv) the absence of a significant reduction in the energy of binding between pyrimethamine and the modeled PmDHFR enzyme observed in computational analysis (8) , and (v) the difference in amino acid composition at codon 206 between sequences of Plasmodium brasilianum (valine) and Plasmodium malariae (isoleucine). All these indications lead us to suggest that the Pmdhfr wildtype sequence carries a glutamine at residue 22.
Compared to previous data, seven new mutations (at positions 55, 58, 59, 168, 194, 207, and 221) were observed exclusively in Malagasy samples, while the African isolates presented no mutations and the Cambodian samples presented only one mutation (S114N), already found in Thai samples. In total, nine haplotypes were found among our samples: two were shared with the sequences of Tanomsing et al. (37) (the wild-type haplotype and the S114N haplotype shared by Cambodian and Thai P. malariae sequences), and seven (exclusively from Malagasy samples) have never been described previously. However, the prevalences of these new haplotypes were very low (from 0.80% to 3.25%) compared to that of the wild type (91.05%). Among the new haplotypes, two were classified as double mutant type (S59A D207S and S58R F168S), while the others were classified as single mutant type (S59A, S114N, T221A, N194S, and K55S). Of the four mutations (leading to changes in residues 50, 58, 114, and 170) previously found to be associated with pyrimethamine resistance in P. falciparum and P. vivax (Fig. 2) , only two were observed in our samples: S58R in one Malagasy sample (0.80%) and S114N in three Cam-
FIG 2
Correspondence between polymorphisms in the P. malariae dhfr gene and equivalent residues known to be related to pyrimethamine resistance in the P. falciparum and P. vivax dhfr genes. For P. falciparum and P. vivax, codons resulting from nonsynonymous mutations related to pyrimethamine resistance are indicated by boldface and shading. For P. malariae, codons likely related to pyrimethamine resistance are indicated by boldface and shading, while those close to SNP involved in P. falciparum or P. vivax pyrimethamine resistance are shown in boldface only. P. malariae codons in italics correspond to mutations described previously by Tanomsing et al. (37) . bodian isolates (2.40%). We did not find mutations at position 50 (observed in one Lao People's Democratic Republic sample) or 170 (observed in one Vietnamese sample) in our set of samples. Recent data from in silico experiments on binding between modeled Pmdhfr mutant sequences and antifolates revealed that certain residues (I13, L45, D53, S117, and I170) appear to play important roles in binding with pyrimethamine (8) . Among the mutations (N50K, S58R, S114N, I170M) found in field isolates from their previous work (37) that correlate with those seen in PfDHFR and PvDHFR, the authors showed that only the Pmdhfr I170M mutant type was associated with a significant reduction in docking energy for pyrimethamine, suggesting differences between species in terms of the ability of the DHFR enzyme to tolerate mutations. Three other mutations close to SNP involved in pyrimethamine resistance (K55E, S59A, and F168S) were also found in Malagasy samples. These mutations were not directly studied by Choowongkomon et al. (8) in their experiments, but they could have indirect implications for ligand binding by DHFR enzymes. For example, we cannot exclude the possibility that the S59A mutation was selected by antifolate drug pressure, since it is closely related to the S58R mutation, or that the mutation observed at codon F168S, which is closely related to I170M, would be an important target for the selection pressure of pyrimethamine resistance against PmDHFR. Further studies involving heterologous expression of the PmDHFR mutants found in our study would be useful in addressing this issue.
Comparing P. malariae dhfr sequences in Cambodian, Malagasy, and African populations, we observed greater haplotype and nucleotide diversity among the Malagasy P. malariae population. These data could be explained partly by the fact that the prevalence of P. malariae infections is about 10-fold higher in Madagascar than in Cambodia (4, 20) . In both populations, wild-type P. malariae isolates were largely predominant (around 85%). In the Cambodian population, only one mutant type haplotype (114N) that correlates with P. falciparum or P. vivax mutant type haplotypes was observed, suggesting that this allele was selected when SP was used as an antimalarial in the 1980s (19) . In Madagascar, P. malariae DHFR mutant type alleles are more polymorphic, a pattern likely related to the pyrimethamine pressure exerted with the increased use of SP since the implementation of intermittent preventive treatment (IPT) for pregnant women (28) .
In conclusion, polymorphism in the Plasmodium malariae dhfr gene appears to be low compared to that in its sympatric Plasmodium species. However, according to our data from Cambodian and Malagasy isolates, local epidemiology and SP drug pressure history influence the selection of DHFR mutations, as is the case for P. falciparum and P. vivax. Additional studies comparing dhfr sequences in Plasmodium species from the same population or from patients with mixed infections would be worthwhile.
